The role of endothelial PI3Kγ activity in neutrophil trafficking
Phosphoinositide 3-kinase gamma (PI3Kγ) in neutrophils plays a critical role in the directed migration of these cells into inflamed tissues. In this study, we demonstrate the importance of the endothelial component of PI3Kγ activity relative to its leukocyte counterpart in supporting neutrophil inte...
Saved in:
Published in: | Blood Vol. 106; no. 1; pp. 150 - 157 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Elsevier Inc
01-07-2005
The American Society of Hematology |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Phosphoinositide 3-kinase gamma (PI3Kγ) in neutrophils plays a critical role in the directed migration of these cells into inflamed tissues. In this study, we demonstrate the importance of the endothelial component of PI3Kγ activity relative to its leukocyte counterpart in supporting neutrophil interactions with the inflamed vessel wall. Despite the reconstitution of class-Ib PI3K function in neutrophils of p110γ–/– mice, we observed a 45% reduction in accumulation of these cells in an acute lung injury model. Mechanistically, this appears to result from a perturbation in selectin-mediated adhesion as manifested by a 70% reduction in wild-type (WT) neutrophil attachment to and 17-fold increase in rolling velocities on p110γ–/– microvessels in vivo in response to tumor necrosis factor alpha (TNFα). This alteration in adhesion was further augmented by a deficiency in p110δ, suggesting that the activity of both catalytic subunits is required for efficient capture of neutrophils by cytokine-stimulated endothelium. Interestingly, E-selectin–mediated adhesion in p110γ–/– mice was impaired by more than 95%, but no defect in nuclear factor kappa B (NF-κB)–induced gene expression was observed. These findings suggest a previously unrecognized partnership between class-I PI3Ks expressed in leukocytes and endothelium, the combination of which is required for the efficient trafficking of immunocompetent cells to sites of inflammation. |
---|---|
Bibliography: | An Inside Blood analysis of this article appears at the front of the issue. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734. Reprints: Thomas G. Diacovo, Department of Pediatrics and Department of Pathology, Columbia University, College of Physicians and Surgeons, 3959 Broadway, CHC115, New York, NY 10032; e-mail: td2142@columbia.edu. Prepublished online as Blood First Edition Paper, March 15, 2005; DOI 10.1182/blood-2005-01-0023. K.D.P., J.D., and J.S.H are employed by ICOS Corporation, the company whose potential product was studied in the present work. Supported by National Institutes of Health grant HL63 244-05 and the American Lung Association (T.G.D.) and the Medical Research Council and Biotechnology and Biological Sciences Research Council (M.T.). |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2005-01-0023 |